Stocks Sanofi SA

More

  • Copenhagen, Denmark

    Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • Denmark is facing its "Nokia moment"; drugmaker Novo Nordisk has ballooned into a $100 billion giant, dominating its home stock market just as the Finnish firm did at the height of the 1990s tech boom.

  • pills.jpg

    The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.

  • prescription-drugs-2_200.jpg

    Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.

  • Flu Reaches Epidemic Level in U.S.

    Widespread influenza activity has afflicted 47 states, according to the CDC. Phil Hosbach, VP of Immunization Policy, discusses whether people should be worried about dwindling supplies.

  • Sanofi CEO on Fighting the Flu

    Chris Viehbacher, CEO of Sanofi, discusses growing concern over the spread of the flu this season.

  • European stocks were flat in early afternoon trading on Monday as fears over a lack of resolution to the U.S.' "fiscal cliff" weighed on sentiment.

  • As Christmas overeating gives way to under-fulfilled new year diets, the pharmaceutical industry's appetite has been whetted for a fresh surge in business.

  • market-insider-stocks-to-watch-AB-200.jpg

    Check out which companies are making headlines after the bell Monday.

  • European shares ended mixed Tuesday amid "fiscal cliff" discussions in the U.S., but losses were limited as EU finance ministers met in Brussels to discuss details of a possible banking union.

  • *Amgen shares rise 1.4 percent. LOS ANGELES, Nov 6- Amgen Inc's experimental cholesterol-lowering drug, AMG145, reduced levels of ``bad'' cholesterol up to 66 percent in patients already taking statin drugs, according to results from a mid-stage trial that were presented on Tuesday.

  • *European Commission clears Glybera for ultra rare disease. The formal clearance from the European Commission paves the way for a launch next summer of the treatment for an ultra rare genetic disease that will cost around 1.2 million euros per patient, a new record for pricey modern medicines.

  • NEW YORK-- Shares of Medidata Solutions Inc. climbed Wednesday after the research software maker said it won a contract with French drugmaker Sanofi. The companies said Sanofi will use Medidata's "cloud" technology to collect and manage clinical data for its entire research and development organization.

  • PARIS, Oct 31- French oil company Total reported a 20 percent rise in third-quarter net adjusted profit to 3.348 billion euros on Wednesday, beating analysts' expectations thanks to a sharp increase in refining margins.

  • Sanofi: Moving Outside of the BRICS

    Christopher Viehbacher, CEO, Sanofi says that as cost rises, the firm is growing its emerging-markets business outside of the BRIC nations.

  • WALTHAM, Mass.-- ImmunoGen Inc. on Friday said that its fiscal first quarter loss widened 29 percent, as it spent more money developing its experimental drugs.

  • Sanofi CEO on Orphan Drugs

    Sanofi CEO Chris Viehbacher offers insight on quarterly earnings, his plans for the company going forward, growth in emerging markets, and the orphan drugs boom.

  • SHRINKING PROFIT: Sanofi saw its earnings slump in the third quarter as generic competitors ate into profits of its Eloxatin cancer treatment. DETAILS: Sanofi earned 1.6 billion for the July-September quarter, down 20 percent from 2 billion a year earlier.

  • TARRYTOWN, N.Y.-- Regeneron Pharmaceuticals Inc. on Wednesday reported third-quarter results that far exceeded Wall Street expectations as it won key new approvals for its eye drug Eylea and cancer drug Zaltrap.

  • NEW YORK-- Isis Pharmaceuticals Inc. said Tuesday that it will get $1.1 million from Alnylam Pharmaceuticals Inc. as part of Alnylam's new collaboration with Genzyme.